119 related articles for article (PubMed ID: 24782555)
1. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
2. A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis.
Sherwood SJ; Tak C; Bhakta ZN; Packer K; Jacobs H; Liou TG; Young DC
Pediatr Pulmonol; 2024 Jun; 59(6):1740-1746. PubMed ID: 38501330
[TBL] [Abstract][Full Text] [Related]
3. Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
Larcombe R; Coulthard K; Eaton V; Tai A; Reuter S; Ward M
Eur J Hosp Pharm; 2024 Jun; 31(4):301-306. PubMed ID: 36600520
[TBL] [Abstract][Full Text] [Related]
4. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.
Mulheran M; Degg C; Burr S; Morgan DW; Stableforth DE
Antimicrob Agents Chemother; 2001 Sep; 45(9):2502-9. PubMed ID: 11502521
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Rybak MJ; Abate BJ; Kang SL; Ruffing MJ; Lerner SA; Drusano GL
Antimicrob Agents Chemother; 1999 Jul; 43(7):1549-55. PubMed ID: 10390201
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.
Hong LT; Liou TG; Deka R; King JB; Stevens V; Young DC
Chest; 2018 Nov; 154(5):1108-1114. PubMed ID: 29908155
[TBL] [Abstract][Full Text] [Related]
8. Daily serum creatinine monitoring promotes earlier detection of acute kidney injury in children and adolescents with cystic fibrosis.
Downes KJ; Rao MB; Kahill L; Nguyen H; Clancy JP; Goldstein SL
J Cyst Fibros; 2014 Jul; 13(4):435-41. PubMed ID: 24718099
[TBL] [Abstract][Full Text] [Related]
9. Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
Garinis AC; Poling GL; Rubenstein RC; Konrad-Martin D; Hullar TE; Baguley DM; Burrows HL; Chisholm JA; Custer A; Hawe LD; Hunter LL; Marras TK; Ortiz CE; Petersen L; Steyger PS; Winthrop K; Zettner EM; Clark K; Hungerford M; Vachhani JJ; Brewer CC
Am J Audiol; 2021 Oct; 30(3S):800-809. PubMed ID: 34549989
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Target Attainment for Tobramycin in Children and Adults with Cystic Fibrosis.
Struiken STL; Lobée D; Tuinen ELV; Touw DJ; Vaart HV; Bourgonje AR; Rottier BL; Koppelman GH; Mian P
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731170
[No Abstract] [Full Text] [Related]
11. Incidence and associated risk factors for systemic drug levels with inhaled aminoglycoside therapy.
Schultheis JM; Durham ME; Kram SJ; Kuhrt M; Gilstrap DL; Parish A; Green CL; Kram BL
J Antimicrob Chemother; 2023 Feb; 78(2):450-456. PubMed ID: 36512376
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycosides: single- or multiple-daily dosing? An updated qualitative systematic review of randomized trials on toxicity and efficacy.
Karimzadeh I; Abdollahpour-Alitappeh M; Ghaffari S; Mahi-Birjand M; Barkhordari A; Alemzadeh E
Curr Mol Med; 2023 Aug; ():. PubMed ID: 37533241
[TBL] [Abstract][Full Text] [Related]
14. Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis.
Hart A; Cesar F; Zelnick LR; O'Connor N; Bailey Z; Lo J; Van Ness K; Stanaway IB; Bammler TK; MacDonald JW; Thau MR; Himmelfarb J; Goss CH; Aitken M; Kelly EJ; Bhatraju PK
J Cyst Fibros; 2024 Mar; 23(2):293-299. PubMed ID: 37949747
[TBL] [Abstract][Full Text] [Related]
15. Implementing services for pediatric cystic fibrosis treatment in a community hospital.
Grube P; Nichols H; Ferrell S; Gilham D; Gaylor A; Dunkelberger K
Am J Health Syst Pharm; 2024 Mar; 81(6):219-225. PubMed ID: 37982450
[TBL] [Abstract][Full Text] [Related]
16. Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review.
Stabler SN; Ensom MH
Can J Hosp Pharm; 2011 May; 64(3):182-91. PubMed ID: 22479053
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.
Haack A; Aragão GG; Novaes MR
World J Gastroenterol; 2013 Dec; 19(46):8552-61. PubMed ID: 24379572
[TBL] [Abstract][Full Text] [Related]
18. Aminoglycoside Therapeutic Drug Monitoring: On Paper vs in Practice.
Narayanan N; Lewis JS
Clin Infect Dis; 2023 Dec; 77(12):1737-1738. PubMed ID: 37517034
[No Abstract] [Full Text] [Related]
19. Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.
Zobell JT; Epps K; Kittell F; Sema C; McDade EJ; Peters SJ; Duval MA; Pettit RS
J Pediatr Pharmacol Ther; 2016; 21(3):239-46. PubMed ID: 27453702
[TBL] [Abstract][Full Text] [Related]
20. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
